Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives
Treatment of acute myeloid leukemia (AML) has improved in recent years and several new therapeutic options have been approved. Most of them include mutation-specific approaches (e.g., gilteritinib for AML patients with activating <i>FLT3</i> mutations), or are restricted to such defined...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/22/5722 |
| _version_ | 1797510949725274112 |
|---|---|
| author | Maximilian Fleischmann Ulf Schnetzke Andreas Hochhaus Sebastian Scholl |
| author_facet | Maximilian Fleischmann Ulf Schnetzke Andreas Hochhaus Sebastian Scholl |
| author_sort | Maximilian Fleischmann |
| collection | DOAJ |
| description | Treatment of acute myeloid leukemia (AML) has improved in recent years and several new therapeutic options have been approved. Most of them include mutation-specific approaches (e.g., gilteritinib for AML patients with activating <i>FLT3</i> mutations), or are restricted to such defined AML subgroups, such as AML-MRC (AML with myeloid-related changes) or therapy-related AML (CPX-351). With this review, we aim to present a comprehensive overview of current AML therapy according to the evolved spectrum of recently approved treatment strategies. We address several aspects of combined epigenetic therapy with the BCL-2 inhibitor venetoclax and provide insight into mechanisms of resistance towards venetoclax-based regimens, and how primary or secondary resistance might be circumvented. Furthermore, a detailed overview on the current status of AML immunotherapy, describing promising concepts, is provided. This review focuses on clinically important aspects of current and future concepts of AML treatment, but will also present the molecular background of distinct targeted therapies, to understand the development and challenges of clinical trials ongoing in AML patients. |
| first_indexed | 2024-03-10T05:38:28Z |
| format | Article |
| id | doaj.art-92d98bbe561a495e8ea86d12d1f69b9f |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T05:38:28Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-92d98bbe561a495e8ea86d12d1f69b9f2023-11-22T22:42:21ZengMDPI AGCancers2072-66942021-11-011322572210.3390/cancers13225722Management of Acute Myeloid Leukemia: Current Treatment Options and Future PerspectivesMaximilian Fleischmann0Ulf Schnetzke1Andreas Hochhaus2Sebastian Scholl3Klinik für Innere Medizin II, Abteilung Hämatologie und Onkologie, Universitätsklinikum Jena, Am Klinikum 1, 07740 Jena, GermanyKlinik für Innere Medizin II, Abteilung Hämatologie und Onkologie, Universitätsklinikum Jena, Am Klinikum 1, 07740 Jena, GermanyKlinik für Innere Medizin II, Abteilung Hämatologie und Onkologie, Universitätsklinikum Jena, Am Klinikum 1, 07740 Jena, GermanyKlinik für Innere Medizin II, Abteilung Hämatologie und Onkologie, Universitätsklinikum Jena, Am Klinikum 1, 07740 Jena, GermanyTreatment of acute myeloid leukemia (AML) has improved in recent years and several new therapeutic options have been approved. Most of them include mutation-specific approaches (e.g., gilteritinib for AML patients with activating <i>FLT3</i> mutations), or are restricted to such defined AML subgroups, such as AML-MRC (AML with myeloid-related changes) or therapy-related AML (CPX-351). With this review, we aim to present a comprehensive overview of current AML therapy according to the evolved spectrum of recently approved treatment strategies. We address several aspects of combined epigenetic therapy with the BCL-2 inhibitor venetoclax and provide insight into mechanisms of resistance towards venetoclax-based regimens, and how primary or secondary resistance might be circumvented. Furthermore, a detailed overview on the current status of AML immunotherapy, describing promising concepts, is provided. This review focuses on clinically important aspects of current and future concepts of AML treatment, but will also present the molecular background of distinct targeted therapies, to understand the development and challenges of clinical trials ongoing in AML patients.https://www.mdpi.com/2072-6694/13/22/5722AMLtargeted therapyclinical trialresistance |
| spellingShingle | Maximilian Fleischmann Ulf Schnetzke Andreas Hochhaus Sebastian Scholl Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives Cancers AML targeted therapy clinical trial resistance |
| title | Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives |
| title_full | Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives |
| title_fullStr | Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives |
| title_full_unstemmed | Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives |
| title_short | Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives |
| title_sort | management of acute myeloid leukemia current treatment options and future perspectives |
| topic | AML targeted therapy clinical trial resistance |
| url | https://www.mdpi.com/2072-6694/13/22/5722 |
| work_keys_str_mv | AT maximilianfleischmann managementofacutemyeloidleukemiacurrenttreatmentoptionsandfutureperspectives AT ulfschnetzke managementofacutemyeloidleukemiacurrenttreatmentoptionsandfutureperspectives AT andreashochhaus managementofacutemyeloidleukemiacurrenttreatmentoptionsandfutureperspectives AT sebastianscholl managementofacutemyeloidleukemiacurrenttreatmentoptionsandfutureperspectives |